Interferon β-1a in relapsing multiple sclerosis: Four-year extension of the European IFNβ-1a Dose-Comparison Study

Michel Clanet; L. Kappos; H. P. Hartung; R. Hohlfeld; W. Kristoferitsch; A. Schrieber; A. Schlederer; P. Seeldrayers; A. Piette; S. Papacostas; K. Kyriallis; A. Pantzaris; B. Brochet; A. Gayou; M. Rouanet; F. Rouant; C. Confavreux; G. Riche; S. Blanc; J. Achiti; C. Magnier; P. Aubertin; C. Mekies; D. Brassat; C. Thalamas; C. Vuilleman; A. Senard; G. Lau; P. Cesaro; F. Degos; G. Defer; S. Schaeffer; G. Edan; A. de Marco; V. Cahagne; S. Belliard; O. Lyon-Caen; B. Stankoff; C. Lubetzki; I. Arnulf; P. Damier; J. Pelletier; D. Tamman; L. Suchet; A. Dalecky; L. Rumbach; A. Moulin; E. Berger; E. Roullet; D. Pez; O. Heinzlef; P. Lecanuet; P. Vermersch; A. Engles; R. Dengler; F. Heidenreich; A. Lindert; A. Koehler; A. Windhagen; A. Steiner; R. Zschenderlein; J. Luenemann; H. Gelderblom; N. Kassim; B. Storch-Hagenlocher; A. Koerner; A. Vogt-Schaden; A. Stingle; A. Storch-Hagenlocher; M. Sailer; A. Matzke; A. Dose; C. Weiler; K. Kunze; C. Heesen; P. Bamborschke; H. Petereit; A. Liu; A. Nolden; F. Grunwald; A. Menck; A. Grupe; P. Rieckmann; A. Weilbach; A. Flachenecker; A. Chan; A. Maurer; J. De Keyser; G. Zwanniken; A. Zorgdrager; X. Montalban; A. Nos; O. Fernandez; J. A. Tamayo; F. Romero; T. Arbizu; A. Martínez-Yélamos; A. Martin; A. Casado

doi:10.1191/1352458504ms990oa

Interferon β-1a in relapsing multiple sclerosis: Four-year extension of the European IFNβ-1a Dose-Comparison Study

Michel Clanet, L. Kappos, H. P. Hartung, R. Hohlfeld, W. Kristoferitsch, A. Schrieber, A. Schlederer, P. Seeldrayers, A. Piette, S. Papacostas, K. Kyriallis, A. Pantzaris, B. Brochet, A. Gayou, M. Rouanet, F. Rouant, C. Confavreux, G. Riche, S. Blanc, J. AchitiC. Magnier, P. Aubertin, C. Mekies, D. Brassat, C. Thalamas, C. Vuilleman, A. Senard, G. Lau, P. Cesaro, F. Degos, G. Defer, S. Schaeffer, G. Edan, A. de Marco, V. Cahagne, S. Belliard, O. Lyon-Caen, B. Stankoff, C. Lubetzki, I. Arnulf, P. Damier, J. Pelletier, D. Tamman, L. Suchet, A. Dalecky, L. Rumbach, A. Moulin, E. Berger, E. Roullet, D. Pez, O. Heinzlef, P. Lecanuet, P. Vermersch, A. Engles, R. Dengler, F. Heidenreich, A. Lindert, A. Koehler, A. Windhagen, A. Steiner, R. Zschenderlein, J. Luenemann, H. Gelderblom, N. Kassim, B. Storch-Hagenlocher, A. Koerner, A. Vogt-Schaden, A. Stingle, A. Storch-Hagenlocher, M. Sailer, A. Matzke, A. Dose, C. Weiler, K. Kunze, C. Heesen, P. Bamborschke, H. Petereit, A. Liu, A. Nolden, F. Grunwald, A. Menck, A. Grupe, P. Rieckmann, A. Weilbach, A. Flachenecker, A. Chan, A. Maurer, J. De Keyser, G. Zwanniken, A. Zorgdrager, X. Montalban, A. Nos, O. Fernandez, J. A. Tamayo, F. Romero, T. Arbizu, A. Martínez-Yélamos, A. Martin, A. Casado

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNβ-1a in patients with relapsing MS from the European IFNβ-1a Dose-Comparison Study. Methods: Patients who completed 36 months of treatment (Part I) of the European IFNβ-1a Dose-Comparison Study were given the option to continue double-blind treatment with IFNβ-1a 30 mcg or 60 mcg IM once weekly (Part 2). Analyses of 48-month data were performed on sustained disability progression, relapses, and neutralizing antibody (NAb) formation. Results. Of 608/802 subjects who completed 36 months of treatment, 493 subjects continued treatment and 446 completed 48 months of treatment and follow-up. IFNβ-1a 30 mcg and 60 mcg IM once weekly were equally effective for up to 48 months. There were no significant differences between doses over 48 months on any of the clinical endpoints, including rate of disability progression, cumulative percentage of patients who progressed (48% and 43%, respectively), and annual relapse rates; relapses tended to decrease over 48 months. The incidence of patients who were positive for NAbs at any time during the study was low in both treatment groups. Conclusion: Compared with 60-mcg IM IFNβ-1a once weekly, a dose of 30 mcg IM IFNβ-1a once weekly maintains the same clinical efficacy over four years.

Original language	English
Pages (from-to)	139-144
Number of pages	6
Journal	Multiple Sclerosis Journal
Volume	10
Issue number	2
DOIs	https://doi.org/10.1191/1352458504ms990oa
State	Published - Apr 2004

Keywords

Interferon beta-1a
Long-term efficacy
Multiple sclerosis
Neutralizing antibodies

Access to Document

10.1191/1352458504ms990oa

Cite this

Clanet, M., Kappos, L., Hartung, H. P., Hohlfeld, R., Kristoferitsch, W., Schrieber, A., Schlederer, A., Seeldrayers, P., Piette, A., Papacostas, S., Kyriallis, K., Pantzaris, A., Brochet, B., Gayou, A., Rouanet, M., Rouant, F., Confavreux, C., Riche, G., Blanc, S., ... Casado, A. (2004). Interferon β-1a in relapsing multiple sclerosis: Four-year extension of the European IFNβ-1a Dose-Comparison Study. Multiple Sclerosis Journal, 10(2), 139-144. https://doi.org/10.1191/1352458504ms990oa

@article{450c4f77f61f47adb726ad22f8138bd4,

title = "Interferon β-1a in relapsing multiple sclerosis: Four-year extension of the European IFNβ-1a Dose-Comparison Study",

abstract = "Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNβ-1a in patients with relapsing MS from the European IFNβ-1a Dose-Comparison Study. Methods: Patients who completed 36 months of treatment (Part I) of the European IFNβ-1a Dose-Comparison Study were given the option to continue double-blind treatment with IFNβ-1a 30 mcg or 60 mcg IM once weekly (Part 2). Analyses of 48-month data were performed on sustained disability progression, relapses, and neutralizing antibody (NAb) formation. Results. Of 608/802 subjects who completed 36 months of treatment, 493 subjects continued treatment and 446 completed 48 months of treatment and follow-up. IFNβ-1a 30 mcg and 60 mcg IM once weekly were equally effective for up to 48 months. There were no significant differences between doses over 48 months on any of the clinical endpoints, including rate of disability progression, cumulative percentage of patients who progressed (48% and 43%, respectively), and annual relapse rates; relapses tended to decrease over 48 months. The incidence of patients who were positive for NAbs at any time during the study was low in both treatment groups. Conclusion: Compared with 60-mcg IM IFNβ-1a once weekly, a dose of 30 mcg IM IFNβ-1a once weekly maintains the same clinical efficacy over four years.",

keywords = "Interferon beta-1a, Long-term efficacy, Multiple sclerosis, Neutralizing antibodies",

author = "Michel Clanet and L. Kappos and Hartung, {H. P.} and R. Hohlfeld and W. Kristoferitsch and A. Schrieber and A. Schlederer and P. Seeldrayers and A. Piette and S. Papacostas and K. Kyriallis and A. Pantzaris and B. Brochet and A. Gayou and M. Rouanet and F. Rouant and C. Confavreux and G. Riche and S. Blanc and J. Achiti and C. Magnier and P. Aubertin and C. Mekies and D. Brassat and C. Thalamas and C. Vuilleman and A. Senard and G. Lau and P. Cesaro and F. Degos and G. Defer and S. Schaeffer and G. Edan and {de Marco}, A. and V. Cahagne and S. Belliard and O. Lyon-Caen and B. Stankoff and C. Lubetzki and I. Arnulf and P. Damier and J. Pelletier and D. Tamman and L. Suchet and A. Dalecky and L. Rumbach and A. Moulin and E. Berger and E. Roullet and D. Pez and O. Heinzlef and P. Lecanuet and P. Vermersch and A. Engles and R. Dengler and F. Heidenreich and A. Lindert and A. Koehler and A. Windhagen and A. Steiner and R. Zschenderlein and J. Luenemann and H. Gelderblom and N. Kassim and B. Storch-Hagenlocher and A. Koerner and A. Vogt-Schaden and A. Stingle and A. Storch-Hagenlocher and M. Sailer and A. Matzke and A. Dose and C. Weiler and K. Kunze and C. Heesen and P. Bamborschke and H. Petereit and A. Liu and A. Nolden and F. Grunwald and A. Menck and A. Grupe and P. Rieckmann and A. Weilbach and A. Flachenecker and A. Chan and A. Maurer and {De Keyser}, J. and G. Zwanniken and A. Zorgdrager and X. Montalban and A. Nos and O. Fernandez and Tamayo, {J. A.} and F. Romero and T. Arbizu and A. Mart{\'i}nez-Y{\'e}lamos and A. Martin and A. Casado",

year = "2004",

month = apr,

doi = "10.1191/1352458504ms990oa",

language = "English",

volume = "10",

pages = "139--144",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "2",

}

Clanet, M, Kappos, L, Hartung, HP, Hohlfeld, R, Kristoferitsch, W, Schrieber, A, Schlederer, A, Seeldrayers, P, Piette, A, Papacostas, S, Kyriallis, K, Pantzaris, A, Brochet, B, Gayou, A, Rouanet, M, Rouant, F, Confavreux, C, Riche, G, Blanc, S, Achiti, J, Magnier, C, Aubertin, P, Mekies, C, Brassat, D, Thalamas, C, Vuilleman, C, Senard, A, Lau, G, Cesaro, P, Degos, F, Defer, G, Schaeffer, S, Edan, G, de Marco, A, Cahagne, V, Belliard, S, Lyon-Caen, O, Stankoff, B, Lubetzki, C, Arnulf, I, Damier, P, Pelletier, J, Tamman, D, Suchet, L, Dalecky, A, Rumbach, L, Moulin, A, Berger, E, Roullet, E, Pez, D, Heinzlef, O, Lecanuet, P, Vermersch, P, Engles, A, Dengler, R, Heidenreich, F, Lindert, A, Koehler, A, Windhagen, A, Steiner, A, Zschenderlein, R, Luenemann, J, Gelderblom, H, Kassim, N, Storch-Hagenlocher, B, Koerner, A, Vogt-Schaden, A, Stingle, A, Storch-Hagenlocher, A, Sailer, M, Matzke, A, Dose, A, Weiler, C, Kunze, K, Heesen, C, Bamborschke, P, Petereit, H, Liu, A, Nolden, A, Grunwald, F, Menck, A, Grupe, A, Rieckmann, P, Weilbach, A, Flachenecker, A, Chan, A, Maurer, A, De Keyser, J, Zwanniken, G, Zorgdrager, A, Montalban, X, Nos, A, Fernandez, O, Tamayo, JA, Romero, F, Arbizu, T, Martínez-Yélamos, A, Martin, A & Casado, A 2004, 'Interferon β-1a in relapsing multiple sclerosis: Four-year extension of the European IFNβ-1a Dose-Comparison Study', Multiple Sclerosis Journal, vol. 10, no. 2, pp. 139-144. https://doi.org/10.1191/1352458504ms990oa

TY - JOUR

T1 - Interferon β-1a in relapsing multiple sclerosis

T2 - Four-year extension of the European IFNβ-1a Dose-Comparison Study

AU - Clanet, Michel

AU - Kappos, L.

AU - Hartung, H. P.

AU - Hohlfeld, R.

AU - Kristoferitsch, W.

AU - Schrieber, A.

AU - Schlederer, A.

AU - Seeldrayers, P.

AU - Piette, A.

AU - Papacostas, S.

AU - Kyriallis, K.

AU - Pantzaris, A.

AU - Brochet, B.

AU - Gayou, A.

AU - Rouanet, M.

AU - Rouant, F.

AU - Confavreux, C.

AU - Riche, G.

AU - Blanc, S.

AU - Achiti, J.

AU - Magnier, C.

AU - Aubertin, P.

AU - Mekies, C.

AU - Brassat, D.

AU - Thalamas, C.

AU - Vuilleman, C.

AU - Senard, A.

AU - Lau, G.

AU - Cesaro, P.

AU - Degos, F.

AU - Defer, G.

AU - Schaeffer, S.

AU - Edan, G.

AU - de Marco, A.

AU - Cahagne, V.

AU - Belliard, S.

AU - Lyon-Caen, O.

AU - Stankoff, B.

AU - Lubetzki, C.

AU - Arnulf, I.

AU - Damier, P.

AU - Pelletier, J.

AU - Tamman, D.

AU - Suchet, L.

AU - Dalecky, A.

AU - Rumbach, L.

AU - Moulin, A.

AU - Berger, E.

AU - Roullet, E.

AU - Pez, D.

AU - Heinzlef, O.

AU - Lecanuet, P.

AU - Vermersch, P.

AU - Engles, A.

AU - Dengler, R.

AU - Heidenreich, F.

AU - Lindert, A.

AU - Koehler, A.

AU - Windhagen, A.

AU - Steiner, A.

AU - Zschenderlein, R.

AU - Luenemann, J.

AU - Gelderblom, H.

AU - Kassim, N.

AU - Storch-Hagenlocher, B.

AU - Koerner, A.

AU - Vogt-Schaden, A.

AU - Stingle, A.

AU - Storch-Hagenlocher, A.

AU - Sailer, M.

AU - Matzke, A.

AU - Dose, A.

AU - Weiler, C.

AU - Kunze, K.

AU - Heesen, C.

AU - Bamborschke, P.

AU - Petereit, H.

AU - Liu, A.

AU - Nolden, A.

AU - Grunwald, F.

AU - Menck, A.

AU - Grupe, A.

AU - Rieckmann, P.

AU - Weilbach, A.

AU - Flachenecker, A.

AU - Chan, A.

AU - Maurer, A.

AU - De Keyser, J.

AU - Zwanniken, G.

AU - Zorgdrager, A.

AU - Montalban, X.

AU - Nos, A.

AU - Fernandez, O.

AU - Tamayo, J. A.

AU - Romero, F.

AU - Arbizu, T.

AU - Martínez-Yélamos, A.

AU - Martin, A.

AU - Casado, A.

PY - 2004/4

Y1 - 2004/4

N2 - Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNβ-1a in patients with relapsing MS from the European IFNβ-1a Dose-Comparison Study. Methods: Patients who completed 36 months of treatment (Part I) of the European IFNβ-1a Dose-Comparison Study were given the option to continue double-blind treatment with IFNβ-1a 30 mcg or 60 mcg IM once weekly (Part 2). Analyses of 48-month data were performed on sustained disability progression, relapses, and neutralizing antibody (NAb) formation. Results. Of 608/802 subjects who completed 36 months of treatment, 493 subjects continued treatment and 446 completed 48 months of treatment and follow-up. IFNβ-1a 30 mcg and 60 mcg IM once weekly were equally effective for up to 48 months. There were no significant differences between doses over 48 months on any of the clinical endpoints, including rate of disability progression, cumulative percentage of patients who progressed (48% and 43%, respectively), and annual relapse rates; relapses tended to decrease over 48 months. The incidence of patients who were positive for NAbs at any time during the study was low in both treatment groups. Conclusion: Compared with 60-mcg IM IFNβ-1a once weekly, a dose of 30 mcg IM IFNβ-1a once weekly maintains the same clinical efficacy over four years.

AB - Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNβ-1a in patients with relapsing MS from the European IFNβ-1a Dose-Comparison Study. Methods: Patients who completed 36 months of treatment (Part I) of the European IFNβ-1a Dose-Comparison Study were given the option to continue double-blind treatment with IFNβ-1a 30 mcg or 60 mcg IM once weekly (Part 2). Analyses of 48-month data were performed on sustained disability progression, relapses, and neutralizing antibody (NAb) formation. Results. Of 608/802 subjects who completed 36 months of treatment, 493 subjects continued treatment and 446 completed 48 months of treatment and follow-up. IFNβ-1a 30 mcg and 60 mcg IM once weekly were equally effective for up to 48 months. There were no significant differences between doses over 48 months on any of the clinical endpoints, including rate of disability progression, cumulative percentage of patients who progressed (48% and 43%, respectively), and annual relapse rates; relapses tended to decrease over 48 months. The incidence of patients who were positive for NAbs at any time during the study was low in both treatment groups. Conclusion: Compared with 60-mcg IM IFNβ-1a once weekly, a dose of 30 mcg IM IFNβ-1a once weekly maintains the same clinical efficacy over four years.

KW - Interferon beta-1a

KW - Long-term efficacy

KW - Multiple sclerosis

KW - Neutralizing antibodies

UR - http://www.scopus.com/inward/record.url?scp=10344255797&partnerID=8YFLogxK

U2 - 10.1191/1352458504ms990oa

DO - 10.1191/1352458504ms990oa

M3 - Article

C2 - 15124757

AN - SCOPUS:10344255797

SN - 1352-4585

VL - 10

SP - 139

EP - 144

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 2

ER -

Interferon β-1a in relapsing multiple sclerosis: Four-year extension of the European IFNβ-1a Dose-Comparison Study

Abstract

Keywords

Access to Document

Fingerprint

Cite this